TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EVE Health Group Limited ( (AU:EVE) ) has provided an announcement.
EVE Health Group Limited has announced the launch of two innovative products, Dyspro and Libbo, targeting the global dysmenorrhoea and erectile dysfunction markets, valued at US$10.92B and US$5.31B respectively. With its patent-pending nano-emulsion technology, the company aims to improve drug delivery speed and effectiveness, having already commenced sales of Dyspro in Australia, with Libbo expected to follow in December.
More about EVE Health Group Limited
EVE Health Group Limited is an emerging pharmaceutical company specializing in fast-acting drug delivery technology. The company focuses on disrupting the underserved women’s health market and has a strong pipeline that includes solutions for men’s health.
Average Trading Volume: 414,510
Technical Sentiment Signal: Sell
Current Market Cap: A$8.12M
For an in-depth examination of EVE stock, go to TipRanks’ Overview page.